



# Vaccine and Infectious Diseases

Collaborate with our dedicated team of experts, offering strategic leadership and tailored support for your Vaccine and Infectious disease clinical trials.

Emmes' Vaccine and Infectious Disease (VID) team harness more than 35 years of clinical development expertise, spanning work in both public and private sectors. We provide full-service support across all phases of clinical development, leveraging deep experience in vaccine research and across select geographies.

With a flexible, rapid approach responding to public health risks, integrated with deep expertise in biostatistics and bioinformatics, Emmes is your VID research partner.

## Services Offerings

Clinical Trial Management

Data Management

Quality Assurance

Pharmacovigilance

Biostatistics & Bioinformatics

Global Regulatory Affairs

## Modernizing clinical research with tech & AI

At Emmes we are modernizing and automating clinical research across the full spectrum of clinical trial activities to operate faster, more efficiently, and with higher quality. We are the industry's first native digital and AI specialty CRO built on a proprietary technology and AI platform.



# What sets us apart?

## Benefits of our services

**Global footprint** - ability to conduct trials in areas and regions where active infection is present, including Latin America, Africa, and Asia.

**Breadth of experience** - Involved in all major global health crises since the 1980s through our partnership with the National Institute of Health (NIH) including HIV, H1N1, MERS, Ebola, Zika, Covid-19, and Monkeypox

**Advanced biostatistics** - statistics driven offerings to support high impact trials including immunogenicity trials, field trials, adaptive trial designs, Bayesian method for assessing efficacy, establishment of correlates of protection.

**Bioinformatics support** - incorporating -omics endpoints into trial design to improve understanding of the immune response and identify surrogates for vaccine protection and/or safety outcomes.

## Highlights Include

**NIH DMD Partnership** - Statistical and Data Coordinating Center for DMID's research of 300+ vaccine & infectious disease protocols since 1996. Providing statistical, data management & operational support for Phase 1-4 clinical trials.

**Rapid COVID-19 Response** - Implemented adaptive trial designs to quickly respond to evolving nature of pandemic. Completed all steps up to randomization of first patient within 4 days or receiving protocol. Reported topline results 3 days after database lock. Achieved EUA approval 70 days from FSFV.

**Ebola Crisis** - Supported a large Phase 2/3 clinical trial enrolling 86,000 subjects globally. Operated in clinical trial naive regions requiring language translation, repeat training, extra attention to data requests and queries. Resulted in NIAID Merit Award in recognition of outstanding performance.

## Key Statistics

35+

Years expertise

650+

VID trials

222,273

Enrolled subjects

350+

Journal publications

For additional information on our Vaccine and Infectious Diseases services, please visit [www.emmes.com](http://www.emmes.com)